Molecular structure of Cilostamide (OPC 3689), CAS Number: 68550-75-4
Cilostamide (OPC 3689) (CAS 68550-75-4)
See product citations (16)
Alternate Names:
Cilostamidum
Application:
Cilostamide (OPC 3689) is a specific phosphodiesterase 3 (PDE3) inhibitor
CAS Number:
68550-75-4
Purity:
≥98%
Molecular Weight:
342.43
Molecular Formula:
C20H26N2O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cilostamide (OPC 3689) is a specific PDE3 (phosphodiesterase 3) inhibitor. The compound may act to block DNA binding of p-Stat3, increase cAMP levels and block the effects of insulin and IGF-1 on meiosis. Additionally, Cilostamide activates K(ATP) channels and produces hyperpolarization in rat mesenteric artery studies. In F/B cells Cliostamide has been reported to inhibit the IGF-1 induced phosphorylation of the apoptotic protein, Bad. Cilostamide (OPC 3689) is a inhibitor of PDE3A and PDE3B.
Cilostamide (OPC 3689) (CAS 68550-75-4) References
- Cyclic nucleotide phosphodiesterase 3B is a downstream target of protein kinase B and may be involved in regulation of effects of protein kinase B on thymidine incorporation in FDCP2 cells. | Ahmad, F., et al. 2000. J Immunol. 164: 4678-88. PMID: 10779773
- A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. | Zhao, AZ., et al. 2002. Nat Neurosci. 5: 727-8. PMID: 12101402
- Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP. | Hanson, MS., et al. 2008. Am J Physiol Heart Circ Physiol. 295: H786-93. PMID: 18586889
- Inhibition of phosphodiesterase has an additive effect on estrogen's ability to inhibit collagen synthesis in vascular smooth muscle cells. | Dimopoulos, GJ. and Langner, RO. 2009. Vascul Pharmacol. 50: 78-82. PMID: 19007913
- Cilostamide produces hyperpolarization associated with K(ATP) channel activation, but does not augment endothelium-derived hyperpolarization in rat mesenteric arteries. | Kansui, Y., et al. 2009. Clin Exp Pharmacol Physiol. 36: 729-33. PMID: 19207721
- Phosphodiesterase inhibition by naloxone augments the inotropic actions of beta-adrenergic stimulation. | Park, WK., et al. 2009. Acta Anaesthesiol Scand. 53: 1043-51. PMID: 19572940
- Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. | Abi-Gerges, A., et al. 2009. Circ Res. 105: 784-92. PMID: 19745166
- Cilostamide and forskolin treatment during pre-IVM improves preimplantation development of cloned embryos by influencing meiotic progression and gap junction communication in pigs. | Park, B., et al. 2016. Theriogenology. 86: 757-65. PMID: 27056415
- Cilostamide and forskolin maintain gap junction function of incubated dog follicles. | Thongkittidilok, C., et al. 2020. Theriogenology. 142: 222-228. PMID: 31629307
- Cilostamide, a phosphodiesterase 3A inhibitor, sustains meiotic arrest of rat oocytes by modulating cyclic adenosine monophosphate level and the key regulators of maturation promoting factor. | Gupta, A. and Trigun, SK. 2022. J Cell Biochem. 123: 2030-2043. PMID: 36125973
- Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. | Verghese, MW., et al. 1995. J Pharmacol Exp Ther. 272: 1313-20. PMID: 7891349
- Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. | Tang, KM., et al. 1994. Eur J Pharmacol. 268: 105-14. PMID: 7925608
- Protein kinase B/Akt induces resumption of meiosis in Xenopus oocytes. | Andersen, CB., et al. 1998. J Biol Chem. 273: 18705-8. PMID: 9668041
Inhibitor of:
AKAP 220, cGKI alpha, CNBD2, CNG-β3, GC kinase, GPR161, Olfr779, Olr483, PDE 3A, PDE3A, PDE3B, PDE6D, RAPGEFL1, SFRS17B, and VPAC2.Activator of:
α-protein kinase 3, 1110008L16Rik, 1300002E11Rik, 1700011H22Rik, 1810010M01Rik, 2310007A19Rik, 2310007B03Rik, 4930458L03Rik, A330021E22Rik, A330050F15Rik, AADAC, ABHD7, ACN9, acrogranin, ADAL, AKAP 10, AKAP 12, AKAP 14, AKAP 2, AKAP 3, AKAP 7, AKAP 82, AKAP 9, AKIP, APBA2BP, APOBEC4, Arbp, ARL6, ARMC4, ARMC5, ARRDC2, Atase, ATP6E, ATP9BL, ATP9BL2, atrophin-2, Borrelia burgdorferi Osp A, C10orf32, C14orf145, C19orf35, C5orf23, calicin, cAMP-GEFII, CapZIP, CASC1, CCDC124, CCDC152, CCDC3, CCDC85B, CCDC97, CERKL, CGREF1, Chromozym PK, CINAP, CNG-1, COMMD6, CXorf59, CYP21A2, Cypher, DCIR4, EF-CAB9, Emi1, Epac2, EphA7, Epsilon-COP, GALR1, Gm128, GNL3L, GPR3, GRK 5, H2-T10, HAPSTR2, HCN3, HCN4, HOP-1, ICA1L, ICAM-3, IVNS1ABP, KPL2, laeverin_4833403I15Rik, LCA5, LHR, Liprin β2, LMBRD2, LRRC56, LT-β, MARVELD3, MC2-R, MCART6, MCC, Med29, METT5D1, MG50, MOBKL2A, MRGG, MRP-L16, MSG1, MTMR12, MYBPC1, Myosin If, Nap-22, neuroguidin, NIFK, NOP9, NPY2-R, NRK, NUDT3, OB-cadherin, Olfr1094, Olfr790, Olfr791, Olfr792, Olfr794, Olfr798, Olfr799, Olfr8, Olfr800, Olfr801, Olfr802, Olfr803, Olfr804, Olfr805, Olfr806, Olfr807, Olfr808, Olfr809, Olfr810, Olfr811, Olfr813, OR10AD1, OR10P1, OR12D2, OR1A2, OR2A4, OR2B3, OR2F1, OR2H1, OR2J2, OR2W1, OR4D6, OR4E2, OR4K14, OR52N2, OR5K1, OVCH1, OVCH2, PAC2, PAC4, PC1, PDE11A, PDE7B, PDE8A, PDPc, Peptide YY3, PHACTR1, PHKA1, phostensin, PIH1D2, PIRT, PKA IIα reg, PKA IIβ reg, PKAα cat, PKAγ, pki α, PNRC1, Ppp1r3d, PPP1R3E, PPP1R3F, PPP1R3G, PPP1R6, Presenilin 2, Protein Kinase A (PRKAR1A PRKAR1B), PRR7, PYST2, Rab 3C, RAPGEF5, RBMY1E, rcRPE, REEP3, RMP, RNase 13, RNase 8, rotatin, RPS4YX, SDF-2L1, SEMA6B, SerpinA11, sFlt-1, SLC35D3, SLC38A9, SLIRP, SPACR, SPAG16, SPATA7, Suppressin, TAPBPL, Tctex1D2, TIMAP, TMEM118, TMEM25, TPPP, TRF, TSGA13, VAMP-4, VAT1, VMAC, Vmn1r132, Vmn1r160, Vmn2r110, Vmn2r112, Vmn2r114, Vmn2r116, Vmn2r118, Vmn2r123, Vmn2r24, Vmn2r35, Vmn2r37, Vmn2r4, Vmn2r41, Vmn2r43, Vmn2r45, Vmn2r47, Vmn2r49, Vmn2r50, Vmn2r52, Vmn2r54, Vmn2r56, VMO1, VSTM2A, VWA5A, YB-2, ZCCHC5, and ZFPL1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cilostamide (OPC 3689), 5 mg | sc-201180 | 5 mg | $90.00 | |||
Cilostamide (OPC 3689), 25 mg | sc-201180A | 25 mg | $350.00 |